Selma F Mohammed1, Sultan A Mirzoyev2, William D Edwards3, Ahmet Dogan4, Donna R Grogan5, Shannon M Dunlay6, Veronique L Roger7, Morie A Gertz4, Angela Dispenzieri4, Steven R Zeldenrust4, Margaret M Redfield8. 1. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Mayo Graduate School, Mayo Clinic, Rochester, Minnesota. 2. Mayo Medical School, Mayo Clinic, Rochester, Minnesota. 3. Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota. 4. Division of Hematology, Mayo Clinic, Rochester, Minnesota. 5. Clementia Pharmaceuticals, Montreal, Canada. 6. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. 7. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Health Science Research, Mayo Clinic, Rochester, Minnesota. 8. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. Electronic address: redfield.margaret@mayo.edu.
Abstract
OBJECTIVES: This study sought to determine the frequency of left ventricular amyloid in heart failure with preserved ejection fraction (HFpEF). BACKGROUND: Left ventricular amyloid deposition can cause diastolic dysfunction and HFpEF. METHODS: Autopsy of left ventricular specimens from patients with antemortem diagnosis of HFpEF without clinically apparent amyloid (n = 109) and from control subjects (n = 131) were screened with sulfated Alcian blue and subsequent Congo red staining with microdissection for mass spectrometry-based proteomics to determine amyloid type. Fibrosis was assessed with quantitative whole-field digital microscopy. RESULTS: The presence of wild-type transthyretin (wtTTR) amyloid was associated with age at death and male sex, but the age- and sex-adjusted prevalence of wtTTR amyloid was higher in HFpEF patients than in control subjects (odds ratio: 3.8, 95% confidence interval: 1.5 to 11.3; p = 0.03). Among HFpEF patients, moderate or severe interstitial wtTTR deposition, consistent with senile systemic amyloidosis as the primary etiology of HFpEF, was present in 5 (5%) patients (80% men), with mild interstitial and/or variable severity of intramural coronary vascular deposition in 13 (12%) patients. While, wtTTR deposition was often mild, adjusting for age and presence of HFpEF, wtTTR amyloid was associated with more fibrosis (p = 0.005) and lower age, sex, and body size-adjusted heart weight (p = 0.04). CONCLUSIONS: Given the age- and sex-independent association of HFpEF and wtTTR deposition and an emerging understanding of the pathophysiology of the amyloidoses, the current findings support further investigation of the role of wtTTR in the pathophysiology of HFpEF.
OBJECTIVES: This study sought to determine the frequency of left ventricular amyloid in heart failure with preserved ejection fraction (HFpEF). BACKGROUND:Left ventricular amyloid deposition can cause diastolic dysfunction and HFpEF. METHODS: Autopsy of left ventricular specimens from patients with antemortem diagnosis of HFpEF without clinically apparent amyloid (n = 109) and from control subjects (n = 131) were screened with sulfated Alcian blue and subsequent Congo red staining with microdissection for mass spectrometry-based proteomics to determine amyloid type. Fibrosis was assessed with quantitative whole-field digital microscopy. RESULTS: The presence of wild-type transthyretin (wtTTR) amyloid was associated with age at death and male sex, but the age- and sex-adjusted prevalence of wtTTR amyloid was higher in HFpEF patients than in control subjects (odds ratio: 3.8, 95% confidence interval: 1.5 to 11.3; p = 0.03). Among HFpEF patients, moderate or severe interstitial wtTTR deposition, consistent with senile systemic amyloidosis as the primary etiology of HFpEF, was present in 5 (5%) patients (80% men), with mild interstitial and/or variable severity of intramural coronary vascular deposition in 13 (12%) patients. While, wtTTR deposition was often mild, adjusting for age and presence of HFpEF, wtTTR amyloid was associated with more fibrosis (p = 0.005) and lower age, sex, and body size-adjusted heart weight (p = 0.04). CONCLUSIONS: Given the age- and sex-independent association of HFpEF and wtTTR deposition and an emerging understanding of the pathophysiology of the amyloidoses, the current findings support further investigation of the role of wtTTR in the pathophysiology of HFpEF.
Authors: Loek van Heerebeek; Constantijn P M Franssen; Nazha Hamdani; Freek W A Verheugt; G Aernout Somsen; Walter J Paulus Journal: Curr Heart Fail Rep Date: 2012-12
Authors: Akshay K Vaishnaw; Jared Gollob; Christina Gamba-Vitalo; Renta Hutabarat; Dinah Sah; Rachel Meyers; Tony de Fougerolles; John Maraganore Journal: Silence Date: 2010-07-08
Authors: Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer Journal: J Am Coll Cardiol Date: 2019-06-11 Impact factor: 24.094
Authors: Riemer H J A Slart; Andor W J M Glaudemans; Walter Noordzij; Johan Bijzet; Bouke P C Hazenberg; Hans L A Nienhuis Journal: Eur J Nucl Med Mol Imaging Date: 2019-04-23 Impact factor: 9.236
Authors: Kristina Dahlem; Guido Michels; Carsten Kobe; Alexander C Bunck; Henrik Ten Freyhaus; Roman Pfister Journal: Clin Res Cardiol Date: 2017-03-16 Impact factor: 5.460
Authors: Marios Arvanitis; Steven Simon; Gloria Chan; Denise Fine; Paula Beardsley; Michael LaValley; Daniel Jacobson; Clarissa Koch; John L Berk; Lawreen H Connors; Frederick L Ruberg Journal: Amyloid Date: 2017-03 Impact factor: 7.141
Authors: David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer Journal: Can J Cardiol Date: 2016-05-13 Impact factor: 5.223
Authors: Benjamin French; Le Wang; Bonnie Ky; Jeffrey Brandimarto; Anupam Basuray; James C Fang; Nancy K Sweitzer; Thomas P Cappola Journal: J Card Fail Date: 2015-11-10 Impact factor: 5.712